Introduction: thyroid carcinoma is an uncommon malignancy, but its incidence appears to be increasing slowly (female 23.8/100.000 - male 1.22.6/100.000). This is the most common malignant endocrine tumour, represents about 1% of all malignancies. The majority of these patients females, mostly between the age of 3060. The main differentiated histological types are papillary and follicular. The options of the treatment are surgical removal (mainly total), radioiodine therapy (ablation/repeated) and very rarely external beam radiotherapy, chemotherapy. The follow up of the patients are very important (postoperative levothyroxin therapy - TSH suppression and substitution, laboratory - thyroglobulin and thyroglobulin antibodies, ultrasonography).
Method and material: ###341 patients are followed up with differentiated tumor of the thyroid gland at our Endocrinology Clinic continously. As they are regularly controlled, a lot of data are available to screen the patients.
Results: ###8% of the patients had a secondary tumour (secondary primary malignancies), 25 female - 2 male case. The types of the tumours: breast, endometrium, cervix, skin, central nervous system, gastrointestinal tract. 60% of the patients the tumour of the thyroid gland was the first (50% breast cancer was the second tumour, averagely 16 years later than the thyroid), 22% of the patients the thyroid carcinoma was the second tumour (50% breast cancer was the first, followed averagely 7 years later by the thyroid), 18% of the patients unknown the order.
Conclusion: our data confirms that patients with thyroid gland tumours show a higher incidence of secondary malignancies. It emphasizes the role and importance of a follow up screening of the patients for a second malignancy. Furthermore we plan to investigate the oncogenetic background of these tumours.
Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.
Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector
05 - 09 May 2012
European Society of Endocrinology